Biohaven Statistics
Total Valuation
Biohaven has a market cap or net worth of $1.26 billion. The enterprise value is $1.20 billion.
Important Dates
The last earnings date was Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biohaven has 150.56 million shares outstanding. The number of shares has increased by 23.59% in one year.
| Current Share Class | 150.56M |
| Shares Outstanding | 150.56M |
| Shares Change (YoY) | +23.59% |
| Shares Change (QoQ) | +22.82% |
| Owned by Insiders (%) | 10.81% |
| Owned by Institutions (%) | 90.42% |
| Float | 124.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 195.89 |
| PB Ratio | 9.75 |
| P/TBV Ratio | 11.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.41, with a Debt / Equity ratio of 2.21.
| Current Ratio | 7.41 |
| Quick Ratio | 6.68 |
| Debt / Equity | 2.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -333.00% and return on invested capital (ROIC) is -108.56%.
| Return on Equity (ROE) | -333.00% |
| Return on Assets (ROA) | -83.38% |
| Return on Invested Capital (ROIC) | -108.56% |
| Return on Capital Employed (ROCE) | -148.97% |
| Weighted Average Cost of Capital (WACC) | 18.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.36M |
| Employee Count | 274 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Biohaven has paid $1.11 million in taxes.
| Income Tax | 1.11M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.63% in the last 52 weeks. The beta is 3.31, so Biohaven's price volatility has been higher than the market average.
| Beta (5Y) | 3.31 |
| 52-Week Price Change | -47.63% |
| 50-Day Moving Average | 9.50 |
| 200-Day Moving Average | 11.98 |
| Relative Strength Index (RSI) | 36.30 |
| Average Volume (20 Days) | 1,832,486 |
Short Selling Information
The latest short interest is 24.87 million, so 16.51% of the outstanding shares have been sold short.
| Short Interest | 24.87M |
| Short Previous Month | 23.77M |
| Short % of Shares Out | 16.51% |
| Short % of Float | 20.05% |
| Short Ratio (days to cover) | 12.42 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -617.23M |
| Pretax Income | -646.57M |
| Net Income | -647.68M |
| EBITDA | -607.19M |
| EBIT | -617.23M |
| Earnings Per Share (EPS) | -$5.44 |
Full Income StatementBalance Sheet
The company has $347.82 million in cash and $286.18 million in debt, with a net cash position of $61.64 million or $0.41 per share.
| Cash & Cash Equivalents | 347.82M |
| Total Debt | 286.18M |
| Net Cash | 61.64M |
| Net Cash Per Share | $0.41 |
| Equity (Book Value) | 129.50M |
| Book Value Per Share | 0.86 |
| Working Capital | 333.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$594.23 million and capital expenditures -$254,000, giving a free cash flow of -$594.49 million.
| Operating Cash Flow | -594.23M |
| Capital Expenditures | -254,000 |
| Depreciation & Amortization | 10.04M |
| Net Borrowing | 250.00M |
| Free Cash Flow | -594.49M |
| FCF Per Share | -$3.95 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biohaven does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.59% |
| Shareholder Yield | -23.59% |
| Earnings Yield | -51.27% |
| FCF Yield | -47.06% |
Analyst Forecast
The average price target for Biohaven is $21.76, which is 159.36% higher than the current price. The consensus rating is "Buy".
| Price Target | $21.76 |
| Price Target Difference | 159.36% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
